PMID

Data

Article Title

Organization

Sulfonamides as Selective Na

Amgen

Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.

Xenon Pharmaceuticals

Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications.

Merck Research Laboratories

Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain.

Pfizer

Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.

University of Oxford

Engineering potent and selective analogues of GpTx-1, a tarantula venom peptide antagonist of the Na(V)1.7 sodium channel.

Amgen

Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis.

University College London

Ion channels as therapeutic targets: a drug discovery perspective.

Pfizer

A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.

Abbott Laboratories

Imidazopyridines: a novel class of hNav1.7 channel blockers.

Merck Research Laboratories

Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain.

Abbott Laboratories

Novel steroidal saponins, Sch 725737 and Sch 725739, from a marine starfish, Novodinia antillensis.

Schering-Plough Research Institute

Discovery of a novel class of biphenyl pyrazole sodium channel blockers for treatment of neuropathic pain.

Merck Research Laboratories

Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic pain.

Abbott Laboratories

Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives.

Abbott Laboratories

Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.

Abbott Laboratories

Sodium channel blockers.

Purdue Pharma

Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I

Gilead Sciences

Carboxamides as Modulators of Sodium Channels.

Temple University

2-Amino-N-heteroaryl-nicotimamides as Na

Temple University

Discovery of DS-1971a, a Potent, Selective Na

Daiichi Sankyo

Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective NaV1.7 Inhibitors.

Amgen

The discovery and optimization of benzimidazoles as selective Na

Pfizer

Challenges and Opportunities for Therapeutics Targeting the Voltage-Gated Sodium Channel Isoform Na

Siteone Therapeutics

Recent progress in sodium channel modulators for pain.

Pfizer

Discovery of Tarantula Venom-Derived Na

Amgen

Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na

Icagen

Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.

Pfizer